GlassScriptPhysician profile
Ian E Guerrero
NPI 1639604341
$30,233.56
in general payments reported to CMS, 2019-2025
34 companies · $4,641 in 2025
The $4,641 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,517 · 2021: $5,695 · 2022: $6,821 · 2023: $6,512 · 2024: $5,049 · 2025: $4,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Honoraria: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,396.03 |
| Honoraria | $805.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,425.55 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Insmed, INC. | $3,377.40 | 2020-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $2,546.23 | 2020-2025 | |
| Amgen INC. | $2,390.53 | 2020-2025 | Tepezza, Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $2,227.77 | 2021-2025 | |
| Novo Nordisk INC | $2,165.55 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $2,056.68 | 2020-2023 | Krystexxa, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,788.76 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,746.71 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $1,294.14 | 2020-2023 | |
| Glaxosmithkline, LLC. | $1,220.94 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $646.92 | 2023-2025 | Vemlidy, Epclusa |
| Pfizer INC. | $531.30 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $489.71 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $432.08 | 2021-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $359.06 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $311.10 | 2020-2024 | Verquvo, Gardasil, Gardasil 9 |
| Arbor Pharmaceuticals, INC. | $179.68 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $159.02 | 2021-2022 | |
| Exact Sciences Corporation | $149.24 | 2024-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $123.92 | 2021-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $101.67 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $99.93 | 2021-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $79.78 | 2021-2022 | |
| Radius Health, INC. | $67.68 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.90 | 2024 | Caplyta |
| Ironwood Pharmaceuticals, INC | $44.67 | 2020 | |
| Neurocrine Biosciences, INC. | $38.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.00 | 2021 | |
| Leo Pharma INC. | $23.01 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.06 | 2022 | |
| Insulet Corporation | $19.42 | 2024 | Omnipod |
| Abbott Laboratories | $17.52 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $14.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.